Korsana Biosciences, Inc.: BALYASNY ASSET MANAGEMENT L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Balyasny Asset Management L.P. amended its Schedule 13G stake filing for Korsana Biosciences, Inc., according to SEC accession 0001172661-26-005049. The filing updates the asset manager's previously reported beneficial ownership position in the biotech company. Schedule 13G amendments are typically filed by institutional investors whose passive stakes cross or move relative to the 5% reporting threshold. The precise share count and percentage change were not disclosed in the filing summary. Investors will watch for further 13G or 13D filings to gauge whether Balyasny's position is building or being trimmed.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Korsana Biosciences, Inc., Balyasny Asset Management L.P.